Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Research has shown that additional mechanisms of inhibition prevent the majority of patients from successful treatment. Recent studies into the inhibitory role of macrophages portend that these cells are associated with lower survival rate in several different cancer types. In this webinar, Immunologist Prof. Dr. Elfriede Nößner will present her research on specific macrophages in RCC (“ercDCs”) which are associated with poor outcome and their potential as new targets in immune therapy.

 

Learning Objectives